Lentiviral MGMTP140K-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7204-7213

  Phaltane, Ruhi ^a   Lachmann, Nico ^a   Brennig, Sebastian ^a   Ackermann, Mania ^a   Modlich, Ute ^a,b   Moritz, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Gene therapy; Invivo selection; Lentiviral vector; MGMT; UCOE

Indexed keywords

ALKYLATION; GENE THERAPY; PLANTS (BOTANY);

DNA METHYLTRANSFERASES; HEMATOPOIETIC CELL; IN-VIVO; INSERTIONAL MUTAGENESIS; LENTIVIRAL VECTOR; MGMT; TRANSGENE EXPRESSION; UCOE;

VECTORS;

6 O BENZYLGUANINE; CARMUSTINE; COMPLEMENTARY DNA; LENTIVIRUS VECTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHOGLYCERATE KINASE; UBIQUITOUS CHROMATIN OPENING ELEMENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHROMATIN; GUANINE; O(6)-BENZYLGUANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE MARROW; BONE MARROW CELL; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GRANULOCYTOPENIA; HEMATOPOIETIC CELL; HEMATOPOIETIC GENE THERAPY; IN VIVO STUDY; LYMPHOID CELL; MOUSE; MYELOPROTECTION; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTECTION; PROTEIN EXPRESSION; SPLEEN; STEM CELL; THROMBOCYTOPENIA; THYMUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMISTRY; CHROMATIN; DNA SEQUENCE; GENE THERAPY; GENE VECTOR; GENETICS; HEMATOPOIETIC STEM CELL; LENTIVIRINAE; METABOLISM; MOLECULAR CLONING; TRANSGENE;

MURINAE; SPLEEN FOCUS-FORMING VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; CLONING, MOLECULAR; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; GUANINE; HEMATOPOIETIC STEM CELLS; LENTIVIRUS; MICE; MICE, INBRED C57BL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHOSPHOGLYCERATE KINASE; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSGENES;

EID: 84902079466     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.001     Document Type: Article

References (56)

1. Rivat C., Santilli G., Gaspar H.B., Thrasher A.J. Gene therapy for primary immunodeficiencies. Hum Gene Ther 2012, 23:668-675.
2. Mukherjee S., Thrasher A. Gene therapy for PIDs: progress, pitfalls and prospects. Gene 2013, 525:174-181.
3. Nienhuis A.W. Development of gene therapy for blood disorders: an update. Blood 2013, 122:1556-1564.
4. Zhang L., Thrasher A.J., Gaspar H.B. Current progress on gene therapy for primary immunodeficiencies. Gene Ther 2013, 20:963-969.
5. Antoniou M., Skipper K., Anakok O. Optimizing retroviral gene expression for effective therapies. Hum Gene Ther 2013, 24:363-374.
6. Modlich U., Navarro S., Zychlinski D., Maetzig T., Knoess S., Brugman M.H., et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009, 17:1919-1928.
7. Zychlinski D., Schambach A., Modlich U., Maetzig T., Meyer J., Grassman E., et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008, 16:718-725.
8. Antoniou M., Harland L., Mustoe T., Williams S., Holdstock J., Yague E., et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003, 82:269-279.
9. Williams S., Mustoe T., Mulcahy T., Griffiths M., Simpson D., Antoniou M., et al. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol 2005, 5:17.
10. Lindahl Allen M., Antoniou M. Correlation of DNA methylation with histone modifications across the HNRPA2B1-CBX3 ubiquitously-acting chromatin open element (UCOE). Epigenetics 2007, 2:227-236.
11. Zhang F., Frost A., Blundell M., Bales O., Antoniou M., Thrasher A. Aubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010, 18:1640-1649.
12. Zhang F., Thornhill S., Howe S., Ulaganathan M., Schambach A., Sinclair J., et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 2007, 110:1448-1457.
13. Brendel C., Müller-Kuller U., Schultze-Strasser S., Stein S., Chen-Wichmann L., Krattenmacher A., et al. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 2012, 19:1018-1029.
14. Talbot G., Waddington S., Bales O., Tchen R., Antoniou M. Desmin-regulated lentiviral vectors for skeletal muscle gene transfer. Mol Ther 2010, 18:601-608.
15. Flasshove M., Moritz T., Bardenheuer W., Seeber S. Hematoprotection by transfer of drug-resistance genes. Acta Haematol 2003, 110:93-106.
16. Lachmann N., Brennig S., Phaltane R., Flasshove M., Dilloo D., Moritz T. Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy. Neoplasia 2013, 15:239-248.
17. Moritz T., Williams D.A. Marrow protection - transduction of hematopoietic cells with drug resistance genes. Cytotherapy 2001, 3:67-84.
18. Milsom M.D., Williams D.A. Live and let die: invivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) 2007, 6:1210-1221.
19. Neff T., Beard B.C., Kiem H.P. Survival of the fittest: invivo selection and stem cell gene therapy. Blood 2006, 107:1751-1760.
20. Cai S., Ernstberger A., Wang H., Bailey B.J., Hartwell J.R., Sinn A.L., et al. Invivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector. Exp Hematol 2008, 36:283-292.
21. Cai S., Hartwell J.R., Cooper R.J., Juliar B.E., Kreklau E., Abonour R., et al. Invivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells. Mol Ther 2006, 13:1016-1026.
22. Cai S., Wang H., Bailey B., Hartwell J.R., Silver J.M., Juliar B.E., et al. Differential secondary reconstitution of invivo-selected human SCID-repopulating cells in NOD/SCID versus NOD/SCID/gamma chain mice. Bone Marrow Res 2010, 2011:252953.
23. Giordano F.A., Sorg U.R., Appelt J.U., Lachmann N., Bleier S., Roeder I., et al. Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy. Hum Gene Ther 2011, 22:697-710.
24. Milsom M.D., Jerabek-Willemsen M., Harris C.E., Schambach A., Broun E., Bailey J., et al. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res 2008, 68:6171-6180.
25. Pollok K.E., Hartwell J.R., Braber A., Cooper R.J., Jansen M., Ragg S., et al. Invivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 2003, 14:1703-1714.
26. Sawai N., Zhou S., Vanin E.F., Houghton P., Brent T.P., Sorrentino B.P. Protection and invivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 2001, 3:78-87.
27. Zielske S.P., Reese J.S., Lingas K.T., Donze J.R., Gerson S.L. Invivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. JClin Invest 2003, 112:1561-1570.
28. Phaltane R., Haemmerle R., Rothe M., Modlich U., Moritz T. Efficiency and safety of O(6)-methylguanine DNA methyltransferase (MGMT(P140K)-mediated invivo selection in a humanized mouse model. Hum Gene Ther 2014, 25:144-155.
29. Beard B.C., Sud R., Keyser K.A., Ironside C., Neff T., Gerull S., et al. Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood 2009, 113:5094-5103.
30. Beard B.C., Trobridge G.D., Ironside C., McCune J.S., Adair J.E., Kiem H.P. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. JClin Invest 2010, 120:2345-2354.
31. Gerull S., Beard B., Peterson L., Neff T., Kiem H.-P. Invivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 2007, 18:451-456.
32. Gori J.L., Beard B.C., Ironside C., Karponi G., Kiem H.P. Invivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. Cancer Gene Ther 2012, 19:523-529.
33. Kiem H.P., Wu R., Sun G., von Laer D., Rossi J., Trobridge G. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection invivo. Gene Ther 2010, 17:37-49.
34. Neff T., Beard B.C., Peterson L.J., Anandakumar P., Thompson J., Kiem H.P. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005, 105:997-1002.
35. Neff T., Horn P., Peterson L., Thomasson B., Thompson J., Williams D., et al. Methylguanine methyltransferase-mediated invivo selection and chemoprotection of allogeneic stem cells in a large-animal model. JClin Invest 2003, 112:1581-1588.
36. Adair J.E., Beard B.C., Trobridge G.D., Neff T., Rockhill J.K., Silbergeld D.L., et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 2012, 4:133ra57.
37. Jansen M., Sorg U.R., Ragg S., Flasshove M., Seeber S., Williams D.A., et al. Hematoprotection and enrichment of transduced cells invivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther 2002, 9:737-746.
38. Lachmann N., Brennig S., Pfaff N., Schermeier H., Dahlmann J., Phaltane R., et al. Efficient invivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system. Gene Ther 2012, 20:298-307.
39. Ragg S., Xu-Welliver M., Bailey J., D'Souza M., Cooper R., Chandra S., et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to invivo selection of hematopoietic stem cells. Cancer Res 2000, 60:5187-5195.
40. Bock C., Reither S., Mikeska T., Paulsen M., Walter J., Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005, 21:4067-4068.
41. Ackermann M., Lachmann N., Hartung S., Eggenschwiler R., Pfaff N., Happle C., et al. Promoter and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent stem cell-based gene therapy. Biomaterials 2014, 35:1531-1542.
42. Pfaff N., Lachmann N., Ackermann M., Kohlscheen S., Brendel C., Maetzig T., et al. Aubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells (Dayton, Ohio) 2013, 31:488-499.
43. Trobridge G.D., Beard B.C., Wu R.A., Ironside C., Malik P., Kiem H.P. Stem cell selection invivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One 2012, 7:e45173.
44. Trobridge G.D., Wu R.A., Beard B.C., Chiu S.Y., Munoz N.M., von Laer D., et al. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after invivo selection. PLoS One 2009, 4:e7693.
45. Larochelle A., Choi U., Shou Y., Naumann N., Loktionova N.A., Clevenger J.R., et al. Invivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. JClin Invest 2009, 119:1952-1963.
46. Modlich U., Bohne J., Schmidt M., von Kalle C., Knoss S., Schambach A., et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108:2545-2553.
47. Montini E., Cesana D., Schmidt M., Sanvito F., Bartholomae C.C., Ranzani M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. JClin Invest 2009, 119:964-975.
48. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006, 24:687-696.
49. Chang A., Stephan M., Lisowski L., Sadelain M. Erythroid-specific human factor IX delivery from invivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol Ther 2008, 16:1745-1752.
50. Chinnasamy D., Fairbairn L.J., Neuenfeldt J., Treisman J.S., Hanson J.P., Margison G.P., et al. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum Gene Ther 2004, 15:758-769.
51. Robert-Richard E., Richard E., Malik P., Ged C., de Verneuil H., Moreau-Gaudry F. Murine retroviral but not human cellular promoters induce invivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther 2007, 15:173-182.
52. Schambach A., Bohne J., Chandra S., Will E., Margison G.P., Williams D.A., et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006, 13:391-400.
53. Bauer T., Olson E., Huo Y., Tuschong L., Allen J., Li Y., et al. Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter. Gene Ther 2011, 18:553-559.
54. Knight S., Zhang F., Mueller-Kuller U., Bokhoven M., Gupta A., Broughton T., et al. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. JVirol 2012, 86:9088-9095.
55. Kustikova O., Wahlers A., Kuhlcke K., Stahle B., Zander A., Baum C., et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003, 102:3934-3937.
56. Modlich U., Kustikova O.S., Schmidt M., Rudolph C., Meyer J., Li Z., et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005, 105:4235-4246.